explore -WSS

explore

author：leisure time 2025-09-30 11:06:51 - browse：289

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

WSS

For longer

Study on Amgen’s bispecific immunotherapy produces positive data

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

UnitedHealth argues against case alleging wrongful AI care denials

CZI to create biohub to build anti

Citing H5N1 threat, CDC urges peak flu monitoring this summer

focus

explore

focus

Medical leaders decry Supreme Court decision on affirmative action

For longer

At least 13 dead in Texas as scorching temps continue

As a primary care physician, here's how I hope to partner with AI

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Jerome Adams on the need for new antivirals for Covid

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Apple is now the first public company to be valued at $3 trillion

STAT Summit: Ending the crisis of Black deaths in the U.S.

leisure time

Liver decline slowed by off

STAT Readout Newsletter: Biotech news today

As a primary care physician, here's how I hope to partner with AI

Results on Novartis prostate cancer therapy could expand its use

STAT Summit: Ending the crisis of Black deaths in the U.S.

Fentanyl is making it harder to start addiction treatment

Wikipedia

Wikipedia

Wikipedia

Wikipedia